Last month a patient came to my clinic after a third hospitalization for acute suicidal ideation. Medically cleared, discharged, back in the waiting room — the same cycle I’ve watched repeat across hundreds of patients over two decades. The discharge note listed the plan: follow up with outpatient psychiatry. No rapid-acting agent. No bridge. Just a handoff and a prayer that the window between crisis and the next appointment stays closed.
France closed that window in March 2026. The French drug regulatory agency issued the first national authorization anywhere in the world for intravenous racemic ketamine specifically indicated for adult severe suicidal crisis. The approval is narrow and deliberate — an acute-use indication, not a chronic maintenance license — but its precision is exactly the point. Regulators named the target: imminent suicide risk, no approved pharmacological alternative that acts fast enough to matter.
The Gap Spravato Doesn’t Fill
The conventional industry assumption has been that Johnson & Johnson’s esketamine nasal spray, Spravato, approved by the FDA in 2020 for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior, already occupies this space. It does not — not fully. Spravato’s acute suicidal ideation indication requires two doses over 24 hours in a certified healthcare setting under the existing REMS program, and the evidence base for that label was built around patients who were already somewhat stabilized. The French authorization targets the emergency room, the inpatient unit, the moment before stabilization is possible.
Racemic ketamine — the 50/50 mixture of R- and S-ketamine that has been used off-label in IV form for years — acts within hours, not days. In my practice, having treated more than 30,000 patients through guided ketamine therapy, the clinical response curve is unmistakable: for patients in the deepest depressive troughs, the IV racemic formulation often produces a perceptible shift within the first session that no oral antidepressant replicates in under six weeks. The French regulators are not discovering something clinicians didn’t know. They are simply saying it out loud in a regulatory document for the first time.
The neuropharmacology underneath this approval matters for trial designers. Racemic ketamine’s R-enantiomer contributes NMDA antagonism with a different receptor binding profile than the S-enantiomer alone, and there is emerging evidence that the R-ketamine component may drive sustained antidepressant effects with a lower dissociative burden. A 2023 paper in the Journal of Psychopharmacology examining enantiomer-specific signaling suggested the full racemic mixture may produce a synergistic AMPA receptor potentiation that neither enantiomer achieves independently. That is not a settled question — but it is exactly the kind of mechanistic uncertainty that makes a standalone IV racemic ketamine approval scientifically interesting and commercially consequential.
What the FDA Is Watching Now
The FDA has never been comfortable with racemic ketamine as a psychiatric product. The scheduling history, the abuse liability profile, the absence of a proprietary sponsor willing to fund a full NDA package — all of it has kept IV racemic ketamine in the off-label category in the United States despite decades of clinical use. The French approval changes the regulatory conversation because it creates a precedent an FDA division can be asked about directly, at a Type B meeting, with a specific comparator country and a specific indication on the table.
Sponsors designing acute suicidal crisis trials should read the French authorization as a signal, not a blueprint. The U.S. pathway will require its own endpoint architecture. The Columbia Suicide Severity Rating Scale remains the FDA’s preferred primary endpoint in this space, but the agency’s 2023 guidance on suicidality assessment in clinical trials emphasizes that change from baseline scores in acutely suicidal inpatient populations must be paired with meaningful time-to-event data — specifically, time to resolution of active suicidal crisis. That is a hard endpoint to capture in an ED or inpatient setting without a highly coordinated site infrastructure.
Which is where the operational reality bites back.
Running the Trial That Matches the Indication
Enrolling acutely suicidal patients is among the hardest recruitment problems in psychiatry. IRBs are cautious, hospital systems are slow to contract, and the consent process for someone in active crisis requires bilingual staff, flexible timing, and a site team that understands the difference between capacity assessment and exclusion. In my experience running SUD and mood disorder trials across multi-site settings, the protocols that fail enrollment fastest are the ones written by teams who have never watched a consent conversation happen at 2 a.m. in a busy inpatient unit.
A site capable of running this trial needs existing relationships with inpatient psychiatry units, ED psychiatric liaison programs, and crisis stabilization centers — not just an outpatient clinic willing to add a visit. The patient population France just put on the regulatory map is predominantly treatment-refractory, frequently dual-diagnosis, and disproportionately drawn from underserved communities where Spanish-language consent capacity alone eliminates most existing research sites. The IV administration requirement adds an additional layer: nursing protocols, monitoring windows, and REMS-adjacent safety infrastructure that outpatient ketamine clinics are not built for.
The next signal worth watching is whether any U.S. sponsor files an IND for IV racemic ketamine with an acute suicidal ideation primary indication in the next 18 months. If the French authorization generates that conversation at FDA, the endpoint negotiation that follows will define the entire rapid-acting antidepressant trial landscape for the decade ahead.
References
- The Lancet — “[Correspondence] Suicidal crisis: first regulatory approval of IV racemic ketamine” (March 2026)
- FDA Guidance — Suicidality: Prospective Assessment of Occurrence in Clinical Trials (2023 update)
- Journal of Affective Disorders — Largest ketamine treatment outcomes study for mood disorders (Vando et al.)
- FDA — Spravato (esketamine) prescribing information and REMS program documentation (2020)
Dr. Leonardo Vando, MD is Principal Investigator of Psychiatry at Vando Medical Services.
